Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1532 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Ehlers-Danlos Syndrome, Musculocontractural Type, 1 | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| EDSMC1 | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Ehlers-Danlos syndrome, musculocontractural type, 1 (EDSMC1; MIM 601776) is an autosomal recessive variant of Ehlers-Danlos syndrome (EDS) caused by mutations in the carbohydrate sulfotransferase 14 gene (CHST14). The musculocontractural type of Ehlers-Danlos syndrome was formerly known as EDS, type VIB, the kyphoscoliotic type of EDS (with normal lysyl hydroxylase activity) or adducted thumb-clubfoot syndrome. In addition to progressive kyphoscoliosis, patients with the musculocontractural type of Ehlers-Danlos syndrome have several characteristic findings including a severely wasted build, adducted thumbs in infancy, clubfoot, arachnodactyly, joint hypermobility, hyperextensible and fragile skin with atrophic scars, and delayed wound healing. Many patients have dysmorphic facial features that may include hypertelorism, brachycephaly, retrognathia, a broad and flat forehead, thin upper lip, downslanting palpebral fissures, low set ears and facial asymmetry with protruding jaw in older children. Numerous instances of gross motor developmental delay and recurrent large hematomas have been noted. CHST14 encodes dermatan-4-sulfotransferase 1, an enzyme involved in the biosynthesis of dermatan sulfate. Dermatan sulfate is a component of dermatan sulfate proteoglycans, molecules with a wide tissue distribution. Functions ascribed to dermatan sulfate proteoglycans via binding to various other molecules include organization of the extracellular matrix, anticoagulation, cell adhesion, migration and proliferation. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| CHST14 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 601776 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Connective Tissue, Skin | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.